(Q53946960)

English

Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

0 references

amoxicillin/clavulanic acid

1 reference

based on heuristic

inferred from title

piperacillin/tazobactam

1 reference

based on heuristic

inferred from title

author name string

R Speich

1

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

E Imhof

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

M Vogt

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

M Grossenbacher

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

W Zimmerli

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

publication date

1 May 1998

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

European Journal of Clinical Microbiology & Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

17

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

313-317

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Piperacillin therapy for serious bacterial infections.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Effectiveness and tolerance of piperacillin in 333 patients].

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Piperacillin: a review of clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meeting the challenges of beta-lactamases

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survey of Bacteroides fragilis group susceptibility patterns in Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains

1 reference

https://pubmed.ncbi.nlm.nih.gov/9721959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S100960050074

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/9721959

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53946960&oldid=1562877944"